StockData
RenovoRx, Inc. logo

RenovoRx, Inc. (RNXT) stock

RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$1.04+0.09 (+8.91%)

Close on Nov 17, 2026Market cap $46.93MP/E –Yield –

RenovoRx operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

RenovoRx's operating income for the twelve months ending Jun 30, 2026 was -$13.54M. For fiscal 2025 it was -$12.51M. The highest annual figure on record is -$3.20M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.51M–
FY2024Dec 31, 2024-$10.97M–
FY2023Dec 31, 2023-$11.40M–
FY2022Dec 31, 2022-$9.95M–
FY2021Dec 31, 2021-$5.67M–
FY2020Dec 31, 2020-$3.20M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.35M–
Q1 FY2026Mar 31, 2026-$3.47M–
Q4 FY2025Dec 31, 2025-$3.52M–
Q3 FY2025Sep 30, 2025-$3.20M–
Q2 FY2025Jun 30, 2025-$2.68M–
Q1 FY2025Mar 31, 2025-$3.11M–
Q4 FY2024Dec 31, 2024-$2.63M–
Q3 FY2024Sep 30, 2024-$2.83M–
Q2 FY2024Jun 30, 2024-$3.03M–
Q1 FY2024Mar 31, 2024-$2.48M–
Q4 FY2023Dec 31, 2023-$1.78M–
Q3 FY2023Sep 30, 2023-$2.98M–
Q2 FY2023Jun 30, 2023-$3.38M–
Q1 FY2023Mar 31, 2023-$3.26M–
Q4 FY2022Dec 31, 2022-$2.17M–
Q3 FY2022Sep 30, 2022-$2.16M–
Q2 FY2022Jun 30, 2022-$2.61M–
Q1 FY2022Mar 31, 2022-$3.01M–
Q4 FY2021Dec 31, 2021-$2.36M–
Q3 FY2021Sep 30, 2021-$1.40M–
Q2 FY2021Jun 30, 2021-$866.00K–
Q1 FY2021Mar 31, 2021-$1.05M–
Q4 FY2020Dec 31, 2020-$639.00K–
Q3 FY2020Sep 30, 2020-$910.00K–

More RenovoRx figures

See a number that looks wrong?